Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Ann Mosegaard Bak University Hospital of Aarhus, Department of Medical Endocrinology, MEA, Nørrebrogade 44, building 2, Aarhus C, DK 8000, Denmark+45 8949 2071; [email protected]

, MD,

Lærke Egefjord University of Aarhus, Department of Pharmacology, The Bartholin Building, Wilhelm Meyers Allé 4, Aarhus, DK 8000, Denmark

, MD,

Michael Gejl University of Aarhus, Department of Pharmacology, The Bartholin Building, Wilhelm Meyers Allé 4, Aarhus, DK 8000, Denmark

, MD,

Charlotte Steffensen University Hospital of Aarhus, Department of Medical Endocrinology, MEA, Nørrebrogade 44, building 2, Aarhus C, DK 8000, Denmark+45 8949 2071; [email protected]

, MD,

Chalotte Willemann Stecher University Hospital of Aarhus, Skejby, Department of Infectious Diseases, Brendstrupgårdsvej 100, Aarhus N, DK 8200, Denmark

, MD,

Kamille Smidt University of Aarhus, Department of Pharmacology, The Bartholin Building, Wilhelm Meyers Allé 4, Aarhus C, DK 8000, Denmark

Birgitte Brock University Hospital of Aarhus, Department of Clinical Pharmacology, The Bartholin Building, Wilhelm Meyers Allé 4, Aarhus, DK 8000, Denmark

, MD PhD &

Jørgen Rungby University of Aarhus, Department of Pharmacology, The Bartholin Building, Wilhelm Meyers Allé 4, Aarhus C, DK 8000, Denmark

show all

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date